drugset / Trial / NCT05237947
Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial
RandomizedParallel-groupDouble-blindPrevention
Summary
This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital organs. There are many types of HPV, and some can cause cancer. The World Health Organization recommends a two-dose schedule for adolescents 9-14 and three doses for individuals 15 years old or older. This study examines whether a single dose of HPV vaccine can reduce the frequency with which women between ages 18-30 become infected with HPV.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2026-08-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cervarix | Vaccine | — | Intramuscular |
| Comparator | Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed | Vaccine | — | Intramuscular |
| Subject | Gardasil 9 | Vaccine | — | Intramuscular |